ArticleExperimental and clinical cardiology2013
Atorvastatin improves endothelial progenitor cell function and reduces pulmonary hypertension in patients with chronic pulmonary heart disease.
Article in Experimental and clinical cardiology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 5 syntheses or guidelines pooled it, 21 citations in OpenAlex.
- Comparative effectiveness of statins for chronic obstructive pulmonary disease patients with pulmonary hypertension: systematic review and network meta-analysis.Frontiers in medicine · 2025Pooled it
- Anti-Inflammatory Drug Therapy in Chronic Subdural Hematoma: A Systematic Review and Meta-Analysis of Prospective Randomized, Double-Blind and Placebo-Controlled Trials.International journal of molecular sciences · 2022Pooled it
- Evaluation of the efficacy of atorvastatin in the treatment for chronic subdural hematoma: a meta-analysis.Neurosurgical review · 2021Pooled it
- Efficacy of Statin Therapy in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis.Scientific reports · 2016Pooled it
- Use of Statins to Augment Progenitor Cell Function in Preclinical and Clinical Studies of Regenerative Therapy: a Systematic Review.Stem cell reviews and reports · 2016Pooled it
- The Role of Endothelial Progenitor Cells in Atherosclerosis and Impact of Anti-Lipemic Treatments on Endothelial Repair.International journal of molecular sciences · 2022Review
- Treatment of pulmonary hypertension associated with COPD: a systematic review.ERJ open research · 2022Article
- Efficacy and safety of statin therapy in pulmonary hypertension: a systematic review and meta-analysis.Annals of translational medicine · 2019Article
- Are statins beneficial for the treatment of pulmonary hypertension?Chronic diseases and translational medicine · 2017Review
- Statins may be beneficial for patients with pulmonary hypertension secondary to lung diseases.Journal of thoracic disease · 2017Article
- Deciphering the genetic and modular connections between coronary heart disease, idiopathic pulmonary arterial hypertension and pulmonary heart disease.Molecular medicine reports · 2016Article
- Vascular Ageing and Exercise: Focus on Cellular Reparative Processes.Oxidative medicine and cellular longevity · 2016Review
- Roles of miRNA-24 in regulating endothelial nitric oxide synthase expression and vascular endothelial cell proliferation.Molecular and cellular biochemistry · 2015Article
- Functional neural-bone marrow pathways: implications in hypertension and cardiovascular disease.Hypertension (Dallas, Tex. : 1979) · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo explore the effects of atorvastatin on the migration and adhesion of endothelial progenitor cells (EPCs) and on pulmonary artery pressure (PAP) in patients with chronic pulmonary heart disease.
methodsA total of 68 patients with chronic pulmonary heart disease were randomly assigned to either a control group (n=35) or a treatment group (n=33). In addition, 30 healthy volunteers (17 male, 13 female) were enrolled as healthy controls. Atorvastatin (20 mg per day) was administered to the treatment group. The migration and adhesion activities of EPCs in peripheral blood were assessed before and six months after the treatment. PAP was measured using echocardiography before and after the treatment.
resultsEPC number, migration ability and adhesion activity in the peripheral blood of patients in the control and treatment groups were lower than in patients in the healthy control group at baseline (all P<0.05). After six months of atorvastatin therapy, the number of EPCs in the treatment group was greater than in the control group (P<0.05). Migration and adhesion functions of EPCs in the treatment group were greater than in the control group (all P<0.05). The reduction in PAP in the treatment group was greater than in the untreated control group following six months of therapy (P<0.05).
conclusionAtorvastatin therapy increased the migration and adhesion activities of EPCs in patients with chronic pulmonary heart disease. Atorvastatin treatment was also associated with a reduction in PAP in these patients.
Indexed as
Identifiers
24294047PMC3716501W1596682425What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.